NO992009L - New trans-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes - Google Patents

New trans-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes

Info

Publication number
NO992009L
NO992009L NO992009A NO992009A NO992009L NO 992009 L NO992009 L NO 992009L NO 992009 A NO992009 A NO 992009A NO 992009 A NO992009 A NO 992009A NO 992009 L NO992009 L NO 992009L
Authority
NO
Norway
Prior art keywords
syndromes
estrogen
prevention
treatment
related diseases
Prior art date
Application number
NO992009A
Other languages
Norwegian (no)
Other versions
NO992009D0 (en
Inventor
Poul Jacobsen
Svend Treppendahl
Paul Stanley Bury
Anders Kanstrup
Lise Brown Christiansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO992009D0 publication Critical patent/NO992009D0/en
Publication of NO992009L publication Critical patent/NO992009L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

Foreliggende oppfinnelse ved- rører terapeutisk aktive forbindelser med formel (I) en fremgangsmåte for fremstilling av de samme forbindelsene, samt farmasøytiske preparater som omfatter forbindelsene. De nye forbindelsene kan anvendes ved forhindring eller behandling av østro- genrelaterte sykdommer eller syndromer.The present invention relates to therapeutically active compounds of formula (I) for a process for the preparation of the same compounds, as well as pharmaceutical compositions comprising the compounds. The new compounds can be used in the prevention or treatment of estrogen-related diseases or syndromes.

NO992009A 1996-10-28 1999-04-27 New trans-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes NO992009L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK120196 1996-10-28
PCT/DK1997/000481 WO1998018774A1 (en) 1996-10-28 1997-10-28 Novel trans-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes

Publications (2)

Publication Number Publication Date
NO992009D0 NO992009D0 (en) 1999-04-27
NO992009L true NO992009L (en) 1999-06-25

Family

ID=8102120

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992009A NO992009L (en) 1996-10-28 1999-04-27 New trans-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes

Country Status (8)

Country Link
EP (1) EP0937059A1 (en)
JP (1) JP2001502706A (en)
AU (1) AU744403B2 (en)
CA (1) CA2269936A1 (en)
IL (1) IL129623A0 (en)
NO (1) NO992009L (en)
WO (1) WO1998018774A1 (en)
ZA (1) ZA979643B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0944613B1 (en) * 1996-12-13 2002-10-09 Chugai Seiyaku Kabushiki Kaisha Benzopyran derivatives
CA2356986A1 (en) * 1998-12-30 2000-07-06 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
NZ527144A (en) 2001-01-24 2005-03-24 Chiesi Farmaceutici S 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
JP4976649B2 (en) * 2004-09-21 2012-07-18 マーシャル エドワーズ，インク． Compound
EP2407462B1 (en) 2004-09-21 2014-07-30 Marshall Edwards, Inc. Substituted chroman derivatives, medicaments and use in therapy
EP2635121B1 (en) 2010-11-01 2020-01-08 MEI Pharma, Inc. Isoflavonoid compounds and methods for the treatment of cancer
HUE054998T2 (en) 2015-02-02 2021-10-28 Mei Pharma Inc Combination therapies for use in the treatment of breast cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340276A (en) * 1964-04-01 1967-09-05 Ciba Geigy Corp 3, 4-diphenyl-chromans
DE1543749A1 (en) * 1966-02-16 1969-12-11 Merck Ag E Process for the preparation of 3,4-cis-4-aryl-isoflavans
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
HUP9702244A3 (en) * 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders

Also Published As

Publication number Publication date
CA2269936A1 (en) 1998-05-07
AU744403B2 (en) 2002-02-21
WO1998018774A1 (en) 1998-05-07
NO992009D0 (en) 1999-04-27
AU4771897A (en) 1998-05-22
EP0937059A1 (en) 1999-08-25
JP2001502706A (en) 2001-02-27
ZA979643B (en) 1998-04-28
IL129623A0 (en) 2000-02-29

Similar Documents

Publication Publication Date Title
MXPA04012965A (en) Viral inhibitors.
HK129093A (en) N-tert-butyl-decahydro-2(3-amino-2-hydroxy-4-phenyl-butyl)isoquinoline-3-carboxamide & asparaginyl derivatives thereof
BR9911488A (en) Compound, use of it, pharmaceutical composition, and processes for the treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound
NO992524L (en) Concentrated bicyclic pyrimidine derivatives
YU56995A (en) ONLY DERIVED INDOLA
BR9810592A (en) Compound, processes for preparing a compound, for treating or preventing diseases of the endocrine system and for the manufacture of a drug, pharmaceutical composition, and, use of a compound
BR9911482A (en) Compound, pharmaceutical composition, use of the compound, and, processes for the treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound
ATE233250T1 (en) SACCHARINE DERIVATIVES AS PROTEOLYTIC ENZYMIN HIBITORS
ATE231496T1 (en) SACCHARINE DERIVATIVES AS PROTEOLYTIC ENZYMIN HIBITORS
LU90366I2 (en) Nasonex
NO179582C (en) Analogous Process for Preparing Therapeutically Active Hydroxamic Acid and N-Hydroxyurea Derivatives
NO971625L (en) Novel peptides with immunomodulatory effects
RU94036745A (en) Galantamine derivatives and pharmaceutical composition
WO2002094796A3 (en) Benzo[g]quinoxaline derivatives as effective compounds against infectious diseases
AU1719392A (en) Leukotriene b4 antagonist
NO992009L (en) New trans-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes
WO2001000617A3 (en) Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the same
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
NO992003L (en) New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes
BR0016678A (en) Compound, pharmaceutical formulation, use of a compound, method for prophylaxis or treatment of an arrhythmia, and, process for preparing a compound
BR9503572A (en) Compound pharmaceutical composition and method of treatment or prevention of a disease
FI916065A0 (en) A process for the preparation of therapeutically useful substituted sulfonamides and related compounds
NO992010L (en) New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes
NO992005L (en) New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes
NO992008L (en) New (+) enantiomers of cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application